Daniel L. Rathbone

Daniel L. Rathbone

Auto-generated profile, based on publicly available information

Daniel L. Rathbone

School of Life and Health Sciences, Aston University, Aston Triangle, B4 7ET, Birmingham, UK

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2012 in Journal of Biological Chemistry
Verified
Journal Article
Open access
ZWZhuo Wang
Zhuo Wang
RCRussell J. Collighan
Russell J. Collighan
KPKamila Pytel
Kamila Pytel
DRDaniel L. Rathbone
Daniel L. Rathbone
XLXiaoling Li
Xiaoling Li
MGMartin Griffin
Martin Griffin
Tissue transglutaminase (TG2) is a multifunctional Ca(2+)-activated protein cross-linking enzyme secreted into the extracellular matrix (ECM), where it is involved in wound healing and scarring, tissue fibrosis, celiac disease, and metastatic cancer. Extracellular TG2 can also facilitate cell adhesion important in wound healing through a nontransamidating mechanism via its association with fibronectin, heparan sulfates (HS), and integrins. Regulating the mechanism how TG2 is translocated into the ECM therefore provides a strategy for modulating these physiological and pathological functions of the enzyme. Here, through molecular modeling and mutagenesis, we have identified the HS-binding site of TG2 (202)KFLKNAGRDCSRRSSPVYVGR(222). We demonstrate the requirement of this binding site for translocation of TG2 into the ECM through a mechanism involving cell surface shedding of HS. By synthesizing a peptide NPKFLKNAGRDCSRRSS corresponding to the HS-binding site within TG2, we also demonstrate how this mimicking peptide can in isolation compensate for the RGD-induced loss of cell adhesion on fibronectin via binding to syndecan-4, leading to activation of PKCα, pFAK-397, and ERK1/2 and the subsequent formation of focal adhesions and actin cytoskeleton organization. A novel regulatory mechanism for TG2 translocation into the extracellular compartment that depends upon TG2 conformation and the binding of HS is proposed.

1 October 2008 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
MGMartin Griffin
Martin Griffin
AMAlexandre Mongeot
Alexandre Mongeot
RCRussell Collighan
Russell Collighan
RSRobert E. Saint
Robert E. Saint
RJRichard A. Jones
Richard A. Jones
DRDaniel L. Rathbone
Daniel L. Rathbone

14 November 2013 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
HWHarriet A Watkins
Harriet A Watkins
DRDan L Rathbone
Dan L Rathbone
JBJames Barwell
James Barwell
DHDebbie L Hay
Debbie L Hay
DPDavid R Poyner
David R Poyner

1 October 2015 in Chemistry & Biology
Verified
Journal Article
Closed access
EBEduard Badarau
Eduard Badarau
ZWZhuo Wang
Zhuo Wang
DRDan L. Rathbone
Dan L. Rathbone
ACAndrea Costanzi
Andrea Costanzi
TTThomas Thibault
Thomas Thibault
MGMartin Griffin
Martin Griffin

27 January 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
RLRose C. Lopeman
Rose C. Lopeman
JHJames Harrison
James Harrison
DRDaniel L. Rathbone
Daniel L. Rathbone
MDMaya Desai
Maya Desai
PLPeter A. Lambert
Peter A. Lambert
Jonathan A.G. CoxJonathan A.G. Cox
Jonathan A.G. Cox
Infections caused by Mycobacterium abscessus are increasing in prevalence in cystic fibrosis patients. This opportunistic pathogen′s intrinsic resistance to most antibiotics has perpetuated an urgent demand for new, more effective therapeutic interventions. Here we report a prospective advance in the treatment of M. abscessus infection; increasing the susceptibility of the organism to amoxicillin, by repurposing the β-lactamase inhibitor, relebactam, in combination with the front line M. abscessus drug imipenem. We establish by multiple in vitro methods that this combination works synergistically to inhibit M. abscessus. We also show the direct competitive inhibition of the M. abscessus β-lactamase, BlaMab, using a novel assay, which is validated kinetically using the nitrocefin reporter assay and in silico binding studies. Furthermore, we reverse the susceptibility by overexpressing BlaMab in M. abscessus, demonstrating relebactam-BlaMab target engagement. Finally, we highlight the in vitro efficacy of this combination against a panel of M. abscessus clinical isolates, revealing the therapeutic potential of the amoxicillin-imipenem-relebactam combination.

1 January 2001 in Inorganic Chemistry Communications
Verified
Journal Article
Closed access
NGNikhil Gokhale
Nikhil Gokhale
SPSubhash Padhye
Subhash Padhye
DRDan Rathbone
Dan Rathbone
DBDavid Billington
David Billington
PLPhillip Lowe
Phillip Lowe
CNChris Newton
Chris Newton